Glioblastoma has high recurrence, while the sensitivity of recurrent
glioblastoma to
chemotherapy is lower than that of primary
glioblastoma. Moreover, there is no standardized treatment for recurrent
glioblastoma. Unfortunately, the biological mechanism of recurrent
glioblastoma is still unclear, and there are few related studies. We compared the phenotypes of clinical
glioblastoma specimens, in-vitro cultured
glioma stem-like cells (GSCs) and patient-derived xenograft
tumor (PDX) models to explore the molecular genetic characteristics of primary and recurrent
glioblastoma from the same patient. In vitro, SU5-2, GSCs derived from recurrent
glioblastoma specimens, had stronger proliferative activity and self-renewal ability. Meanwhile, SU5-2 was more resistant to
temozolomide and invasive than SU5-1, which derived from primary
glioblastoma specimens. Further analysis of the expression of costimulatory molecules showed that the expression of B7-H1, B7-H2 and B7-H3 of SU5-2 were upregulated. In vivo, Kaplan-Meier survival curve analysis showed that the median survival of the recurrent PDX group was worse. The results of gene detection in vitro, PDX model and clinical samples were consistent. Our results showed that the GSCs based on
glioblastoma specimens and the PDX models could replicate the main molecular genetic characteristics of original
tumors, which provided a reliable experimental platform for both
tumor translation kinds of research and screening of molecular therapeutic targets.